The ARC team is deeply committed to amyloidosis and works tirelessly to deliver our programs which are fully integrated across the entire research and development continuum and into the clinic. These closely align with our mission, and focus on the areas that are most important, can best be delivered by ARC and are most likely to have the biggest impact on patients, short- and long-term.
Isabelle Lousada has been the driving force behind ARC, building successful collaborations and programs across the sectors to advance the science and understanding of the amyloidosis diseases.
Isabelle was diagnosed with AL amyloidosis, and was one of the first patients to successfully undergo a stem cell transplant. For the past twenty years she has been committed to empowering other patients while serving on several boards and committees, speaking at leadership meetings and key events to encourage research, increase access, and support the critical and unmet needs of amyloidosis patients.
Sarah was senior partner and managing director of Boston Consulting Group, led BCG’s more than 500-member scientist network, and was a member of the firm’s global social impact, health care, and people and organization leadership teams. Sarah has a BSc in microbiology and genetics from University College London, a PhD in biochemistry from Imperial Cancer Research Fund and London University, and an MBA from Columbia Business. Before business school, Dr. Cairns-Smith was a post-doctoral scientist in the Center for Neurobiology at Columbia University.
Kristen has over ten years of clinical operations experience within the pharmaceutical industry. She has a wealth of experience in managing complex global clinical trials for novel treatments of rare diseases. Kristen is building and overseeing the ARC’s clinical research program and manages a prioritized portfolio of vital research.
Senior Partner and Managing Director, Boston Consulting Group
Founder and CEO, Amyloidosis Research Consortium
Facilitator, Northern California Amyloidosis Support Group
CEO, Patient Discovery
Director, Transfusion Services; Director, John C. Davis Myeloma and Amyloid Program at Tufts Medical Center; Professor, Tufts University School of Medicine
Director, Center for Research and Treatment of Systemic Amyloidosis, and of the Biotechnology Research Laboratories, Scientific Institute Policlinico San Matteo, University of Pavia, Italy
Tufts Medical Center
New York-Presbyterian Hospital/Columbia University Medical Center
University of Pavia
The Scripps Research Institute
Boston Medical Center
Chairman, Amyloidosis Research Consortium-UK
Royal Free Hospital